Thrombotic microangiopathies and the linkage between von Willebrand factor and the alternative complement pathway

Seminars in Thrombosis and Hemostasis

Volumn 40, Issue 5, 2014, Pages 544-550

  Turner, Nancy ^a   Nolasco, Leticia ^a   Nolasco, Jennifer ^a   Sartain, Sarah ^a,b   Moake, Joel ^a  

^a Rice University   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

alternative complement pathway; factor H; thrombotic microangiopathies; VWF

Indexed keywords

COMPLEMENT; COMPLEMENT FACTOR H; POLYMER; VON WILLEBRAND FACTOR; VON WILLEBRAND FACTOR CLEAVING PROTEINASE; COMPLEMENT MEMBRANE ATTACK COMPLEX;

ARTICLE; COMPLEMENT ACTIVATION; COMPLEMENT ALTERNATIVE PATHWAY; CROSS LINKING; ENDOTHELIUM CELL; HEMOLYTIC UREMIC SYNDROME; HUMAN; PAROXYSMAL NOCTURNAL HEMOGLOBINURIA; PRIORITY JOURNAL; PROVOCATION; THROMBOSIS; THROMBOTIC THROMBOCYTOPENIC PURPURA; GENETICS; PATHOPHYSIOLOGY; PHYSIOLOGY;

ATYPICAL HEMOLYTIC UREMIC SYNDROME; COMPLEMENT FACTOR H; COMPLEMENT MEMBRANE ATTACK COMPLEX; COMPLEMENT PATHWAY, ALTERNATIVE; HEMOGLOBINURIA, PAROXYSMAL; HUMANS; PURPURA, THROMBOTIC THROMBOCYTOPENIC; THROMBOSIS; THROMBOTIC MICROANGIOPATHIES; VON WILLEBRAND FACTOR;

EID: 84905223622     PISSN: 00946176     EISSN: 10989064     Source Type: Journal    
DOI: 10.1055/s-0034-1383547     Document Type: Article

References (56)

1. Favaloro E. J. Hemolytic uremic syndrome. Preface. Semin Thromb Hemost: 2010; 36 6 573 574
2. Riedl M., Orth-Höller D., Würzner R. An update on the thrombotic microangiopathies hemolytic uremic syndrome (HUS) and thrombotic thrombocytopenic purpura (TTP). Semin Thromb Hemost: 2014; 40 413 415
3. Turner N. A., Moake J. Assembly and activation of alternative complement components on endothelial cell-anchored ultra-large von Willebrand factor links complement and hemostasis-thrombosis. PLoS ONE: 2013; 8 3 e59372
4. Turner N., Nolasco L., Moake J. Generation and breakdown of soluble ultralarge von Willebrand factor multimers. Semin Thromb Hemost: 2012; 38 1 38 46
5. Nolasco L., Nolasco J., Feng S., Afshar-Kharghan V., Moake J. Human complement factor H is a reductase for large soluble von Willebrand factor multimers-brief report. Arterioscler Thromb Vasc Biol: 2013; 33 11 2524 2528
6. Moake J. L. Thrombotic microangiopathies. N Engl J Med: 2002; 347 8 589 600
7. Furlan M., Robles R., Galbusera M., et al. von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome. N Engl J Med: 1998; 339 22 1578 1584 (Pubitemid 28536132)
8. Furlan M., Robles R., Solenthaler M., Wassmer M., Sandoz P., Lämmle B. Deficient activity of von Willebrand factor-cleaving protease in chronic relapsing thrombotic thrombocytopenic purpura. Blood: 1997; 89 9 3097 3103 (Pubitemid 27229791)
9. Tsai H. M., Lian E. C. Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura. N Engl J Med: 1998; 339 22 1585 1594 (Pubitemid 28536133)
10. Loirat C., Frémeaux-Bacchi V. Atypical hemolytic uremic syndrome. Orphanet J Rare Dis: 2011; 6 1 60
11. Maga T. K., Nishimura C. J., Weaver A. E., Frees K. L., Smith R. JH. Mutations in alternative pathway complement proteins in American patients with atypical hemolytic uremic syndrome. Hum Mutat: 2010; 31 6 E1445 E1460
12. Zipfel P. F., Edey M., Heinen S., et al. Deletion of complement factor H-related genes CFHR1 and CFHR3 is associated with atypical hemolytic uremic syndrome. PLoS Genet: 2007; 3 3 e41
13. Frémeaux-Bacchi V., Miller E. C., Liszewski M. K., et al. Mutations in complement C3 predispose to development of atypical hemolytic uremic syndrome. Blood: 2008; 112 13 4948 4952
14. Goicoechea de Jorge E., Harris C. L., Esparza-Gordillo J., et al. Gain-of-function mutations in complement factor B are associated with atypical hemolytic uremic syndrome. Proc Natl Acad Sci U S A: 2007; 104 1 240 245 (Pubitemid 46068016)
15. Roumenina L. T., Loirat C., Dragon-Durey M. A., Halbwachs-Mecarelli L., Sautes-Fridman C., Fremeaux-Bacchi V. Alternative complement pathway assessment in patients with atypical HUS. J Immunol Methods: 2011; 365 1-2 8 26
16. Law S. K., Levine R. P. Interaction between the third complement protein and cell surface macromolecules. Proc Natl Acad Sci U S A: 1977; 74 7 2701 2705 (Pubitemid 8150803)
17. Pangburn M. K., Ferreira V. P., Cortes C. Discrimination between host and pathogens by the complement system. Vaccine: 2008; 26 8 08 I15 I21
18. Law S. K., Dodds A. W. The internal thioester and the covalent binding properties of the complement proteins C3 and C4. Protein Sci: 1997; 6 2 263 274 (Pubitemid 27079917)
19. Schreiber R. D., Pangburn M. K., Lesavre P. H., Müller-Eberhard H. J. Initiation of the alternative pathway of complement: recognition of activators by bound C3b and assembly of the entire pathway from six isolated proteins. Proc Natl Acad Sci U S A: 1978; 75 8 3948 3952 (Pubitemid 8399848)
20. Fearon D. T., Austen K. F., Ruddy S. Formation of a hemolytically active cellular intermediate by the interaction between properdin factors B and D and the activated third component of complement. J Exp Med: 1973; 138 6 1305 1313
21. Pillemer L., Blum L., Lepow I. H., Ross O. A., Todd E. W., Wardlaw A. C. The properdin system and immunity. I. Demonstration and isolation of a new serum protein, properdin, and its role in immune phenomena. Science: 1954; 120 3112 279 285
22. Weiler J. M., Daha M. R., Austen K. F., Fearon D. T. Control of the amplification convertase of complement by the plasma protein beta1H. Proc Natl Acad Sci U S A: 1976; 73 9 3268 3272
23. Kinoshita T., Takata Y., Kozono H., Takeda J., Hong K. S., Inoue K. C5 convertase of the alternative complement pathway: covalent linkage between two C3b molecules within the trimolecular complex enzyme. J Immunol: 1988; 141 11 3895 3901
24. Rawal N., Pangburn M. Formation of high-affinity C5 convertases of the alternative pathway of complement. J Immunol: 2001; 166 4 2635 2642 (Pubitemid 32173502)
25. Bernardo A., Ball C., Nolasco L., Moake J. F., Dong J. F. Effects of inflammatory cytokines on the release and cleavage of the endothelial cell-derived ultralarge von Willebrand factor multimers under flow. Blood: 2004; 104 1 100 106 (Pubitemid 38879844)
26. Huang J., Motto D. G., Bundle D. R., Sadler J. E. Shiga toxin B subunits induce VWF secretion by human endothelial cells and thrombotic microangiopathy in ADAMTS13-deficient mice. Blood: 2010; 116 18 3653 3659
27. Nolasco L. H., Turner N. A., Bernardo A., et al. Hemolytic uremic syndrome-associated Shiga toxins promote endothelial-cell secretion and impair ADAMTS13 cleavage of unusually large von Willebrand factor multimers. Blood: 2005; 106 13 4199 4209 (Pubitemid 41775927)
28. Klegeris A., Bissonnette C. J., Dorovini-Zis K., McGeer P. L. Expression of complement messenger RNAs by human endothelial cells. Brain Res: 2000; 871 1 1 6 (Pubitemid 30406861)
29. Langeggen H., Berge K. E., Macor P., et al. Detection of mRNA for the terminal complement components C5, C6, C8 and C9 in human umbilical vein endothelial cells in vitro. APMIS: 2001; 109 1 73 78 (Pubitemid 32243476)
30. Langeggen H., Pausa M., Johnson E., Casarsa C., Tedesco F. The endothelium is an extrahepatic site of synthesis of the seventh component of the complement system. Clin Exp Immunol: 2000; 121 1 69 76 (Pubitemid 30436017)
31. Würzner R., Joysey V. C., Lachmann P. J. Complement component C7. Assessment of in vivo synthesis after liver transplantation reveals that hepatocytes do not synthesize the majority of human C7. J Immunol: 1994; 152 9 4624 4629 (Pubitemid 24134423)
32. Cines D. B., Pollak E. S., Buck C. A., et al. Endothelial cells in physiology and in the pathophysiology of vascular disorders. Blood: 1998; 91 10 3527 3561 (Pubitemid 28225719)
33. Hattori R., Hamilton K. K., McEver R. P., Sims P. J. Complement proteins C5b-9 induce secretion of high molecular weight multimers of endothelial von Willebrand factor and translocation of granule membrane protein GMP-140 to the cell surface. J Biol Chem: 1989; 264 15 9053 9060 (Pubitemid 19151636)
34. Réti M., Farkas P., Csuka D., et al. Complement activation in thrombotic thrombocytopenic purpura. J Thromb Haemost: 2012; 10 5 791 798
35. Ruiz-Torres M. P., Casiraghi F., Galbusera M., et al. Complement activation: the missing link between ADAMTS-13 deficiency and microvascular thrombosis of thrombotic microangiopathies. Thromb Haemost: 2005; 93 3 443 452 (Pubitemid 40392531)
36. Chapin J., Weksler B., Magro C., Laurence J. Eculizumab in the treatment of refractory idiopathic thrombotic thrombocytopenic purpura. Br J Haematol: 2012; 157 6 772 774
37. Tsai E., Chapin J., Laurence J. C., Tsai H. M. Use of eculizumab in the treatment of a case of refractory, ADAMTS13-deficient thrombotic thrombocytopenic purpura: additional data and clinical follow-up. Br J Haematol: 2013; 162 4 558 559
38. Feng S., Eyler S. J., Zhang Y., et al. Partial ADAMTS13 deficiency in atypical hemolytic uremic syndrome. Blood: 2013; 122 8 1487 1493
39. Sartz L., Olin A. I., Kristoffersson A. C., et al. A novel C3 mutation causing increased formation of the C3 convertase in familial atypical hemolytic uremic syndrome. J Immunol: 2012; 188 4 2030 2037
40. Delvaeye M., Noris M., De Vriese A., et al. Thrombomodulin mutations in atypical hemolytic-uremic syndrome. N Engl J Med: 2009; 361 4 345 357
41. Endo M., Ware R. E., Vreeke T. M., et al. Molecular basis of the heterogeneity of expression of glycosyl phosphatidylinositol anchored proteins in paroxysmal nocturnal hemoglobinuria. Blood: 1996; 87 6 2546 2557 (Pubitemid 26086901)
42. Holguin M. H., Fredrick L. R., Bernshaw N. J., Wilcox L. A., Parker C. J. Isolation and characterization of a membrane protein from normal human erythrocytes that inhibits reactive lysis of the erythrocytes of paroxysmal nocturnal hemoglobinuria. J Clin Invest: 1989; 84 1 7 17 (Pubitemid 19170089)
43. Yamashina M., Ueda E., Kinoshita T., et al. Inherited complete deficiency of 20-kilodalton homologous restriction factor (CD59) as a cause of paroxysmal nocturnal hemoglobinuria. N Engl J Med: 1990; 323 17 1184 1189 (Pubitemid 20347405)
44. Savage W. J., Barber J. P., Mukhina G. L., et al. Glycosylphosphatidylinositol-anchored protein deficiency confers resistance to apoptosis in PNH. Exp Hematol: 2009; 37 1 42 51
45. Rollins S. A., Sims P. J. The complement-inhibitory activity of CD59 resides in its capacity to block incorporation of C9 into membrane C5b-9. J Immunol: 1990; 144 9 3478 3483 (Pubitemid 20146382)
46. Cole J. L., Housley G. AJ Jr, Dykman T. R., MacDermott R. P., Atkinson J. P. Identification of an additional class of C3-binding membrane proteins of human peripheral blood leukocytes and cell lines. Proc Natl Acad Sci U S A: 1985; 82 3 859 863 (Pubitemid 15142776)
47. Seya T., Atkinson J. P. Functional properties of membrane cofactor protein of complement. Biochem J: 1989; 264 2 581 588 (Pubitemid 20024531)
48. Hill A., Kelly R. J., Hillmen P. Thrombosis in paroxysmal nocturnal hemoglobinuria. Blood: 2013; 121 25 4985 4996, quiz 5105
49. Studt J. D., Kremer Hovinga J. A., Antoine G., et al. Fatal congenital thrombotic thrombocytopenic purpura with apparent ADAMTS13 inhibitor: in vitro inhibition of ADAMTS13 activity by hemoglobin. Blood: 2005; 105 2 542 544 (Pubitemid 40070733)
50. Frimat M., Tabarin F., Dimitrov J. D., et al. Complement activation by heme as a secondary hit for atypical hemolytic uremic syndrome. Blood: 2013; 122 2 282 292
51. Grünewald M., Grünewald A., Schmid A., et al. The platelet function defect of paroxysmal nocturnal haemoglobinuria. Platelets: 2004; 15 3 145 154 (Pubitemid 38651026)
52. Turner N. A., Nolasco L., Ruggeri Z. M., Moake J. L. Endothelial cell ADAMTS-13 and VWF: production, release, and VWF string cleavage. Blood: 2009; 114 24 5102 5111
53. Moake J. L., Turner N. A., Stathopoulos N. A., Nolasco L. H., Hellums J. D. Involvement of large plasma von Willebrand factor (vWF) multimers and unusually large vWF forms derived from endothelial cells in shear stress-induced platelet aggregation. J Clin Invest: 1986; 78 6 1456 1461 (Pubitemid 17219507)
54. Tsai H. M. Physiologic cleavage of von Willebrand factor by a plasma protease is dependent on its conformation and requires calcium ion. Blood: 1996; 87 10 4235 4244
55. Tsai H. M., Sussman I. I., Nagel R. L. Shear stress enhances the proteolysis of von Willebrand factor in normal plasma. Blood: 1994; 83 8 2171 2179 (Pubitemid 24112728)
56. Ripoche J., Day A. J., Harris T. J., Sim R. B. The complete amino acid sequence of human complement factor H. Biochem J: 1988; 249 2 593 602 (Pubitemid 18030952)